5 billion people have access to medicine 2 billion to go


The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Who we are
What we analyse
How we drive change

New online: how pharma companies address access to cancer care

16 pharmaceutical companies | 129 initiatives | 63 countries

There is a growing cancer crisis in the developing world. In this new report, the Foundation analyses how pharmaceutical companies are responding. It finds 16 companies are taking action. Read more >>

News and Events

New study finds wide variety in pharma companies’ cancer access programmes

18 May 2017
The Access to Medicine Foundation has systematically mapped how large research-based pharmaceutical companies are responding to the growing cancer crisis in low and lower-middle income countries.

Foundation Team in Geneva for 70th WHO World Health Assembly

15 May 2017
The Access to Medicine Foundation team will be in Geneva for the 70th WHO World Health Assembly. The Foundation's team will join various side-events focusing on the role of pharmaceutical companies in access to medicine.

The Access to Medicine Foundation has moved!

21 Apr 2017
The Access to Medicine Foundation has outgrown its former office in Haarlem and moved to a larger space in Amsterdam. The new office is close to the Amsterdam Sloterdijk station on Naritaweg 227-A, 1043 CB, Amsterdam.

Out now: the first Access to Vaccines Index

06 Mar 2017
The first Access to Vaccines Index will be published on Monday 6 March, 2017. It is the first tool of its kind to present the current landscape of vaccine company behaviour when it comes to making vaccines more accessible for the populations that need them.

Foundation to track pharma company progress on AMR

13 Dec 2016
The Access to Medicine Foundation has started work on a new tool – an Antimicrobial Resistance Benchmark that will track how pharmaceutical companies are responding to the increase in drug-resistance. The AMR Benchmark is currently funded by the UK and Dutch governments.
Access to Medicine Index Cover

Access to Medicine Index 2016

The only in-depth comparison of the world’s largest pharma companies on how they improve access to medicine for the poor.

Visit website

Access to Vaccines Index Cover

Access to Vaccines Index 2017

The first tool to show how vaccine companies are responding to calls to increase access to vaccines.

Visit website

We’re hiring!

New positions in Research, AMR, Communications
Interested in working toward the next Access to Medicine Index or our new AMR Benchmark? Or in joining the Foundation’s Communications team?


Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.

The foundation on Twitter

Access to Medicine's Twitter avatar
Access to Medicine

Danny's seminar @ Boston U School of Pub. Health (t.co/BAG0xKRsKu) covered methodology for #ATMI2018 –… t.co/DuwZBaXGDj

Tara L Prasad's Twitter avatar
Tara L Prasad

Jay introducing the #AMRBenchmark & her hope it will yield results, ideas & solutions to combat #AMR @ the 2nd Glob… t.co/zzSddvTMQk

Retweeted by Access to Medicine
Access to Medicine's Twitter avatar
Access to Medicine

How can #pharma companies address #AMR? Global Expert Meeting in Tokyo today with @JayasreeKIyer and @TaraLPrasad t.co/O2nhW81cXH

Suzanne Wolf's Twitter avatar
Suzanne Wolf

Work in progress: designing our upcoming methodology report on how to evaluate #pharma on their role & efforts in… t.co/WXkkm18qyv

Retweeted by Access to Medicine
Access to Medicine's Twitter avatar
Access to Medicine

How can #pharma co.s make lasting improvements in access to cancer care? It's a key Q for tomorrow's workshop t.co/iO3zMBWVz9

Encourage pharma companies Access to Medicine


Incentivising pharma to develop medicine for the poor
Which mechanisms work for engaging pharma companies in R&D for diseases of poverty?

“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”

Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.


Embedding pro-access governance


Mainstreaming inclusive business models


Improving industry responsiveness to public health priorities


Employing ‘access-thinking’ in product deployment


Addressing unmet needs through R&D

The Access to Medicine Foundation and its publications are funded by